Brain Health

Four Neurology Drug Approvals Reshaping Brain Disease Treatment

The FDA has approved several landmark neurological drugs in 2024–2025 that mark meaningful advances in brain disease treatment. Kisunla (donanemab) became the second amyloid-targeting therapy approved for Alzheimer's disease in 2024, offering a potential disease-modifying option for early-stage patients. Crexont introduced an extended-release formulation of carbidopa/levodopa for more consistent Parkinson's symptom control. IMAVI (nipocalimab) broke new ground in myasthenia gravis by blocking the FcRn receptor, making it effective for both AChR- and MuSK-positive patients aged 12 and older. Adsumi brought a new nasal powder delivery of dihydroergotamine for acute migraine relief. Together, these approvals reflect accelerating momentum in neurology drug development, offering clinicians and patients new tools across a spectrum of debilitating conditions.